After participating in this educational activity, participants should be better able to: Assess the real-world implications of recent clinical trial findings on SGLT2 inhibitors for disease progression in a diverse patient population with chronic kidney disease (CKD) and/or heart failure (HF) Incorporate the ADA-KDIGO consensus recommendations along with other guidelines, such as ESC-HF, ADA, and AHA, when designing treatment protocols for patients suffering from CKD and/or HF, irrespective of their diabetes status Develop strategies for using SGLT2 inhibitors in patients with and without diabetes to improve cardiorenal outcomes
- Provider:Global Learning Collaborative
- Activity Link: https://www.reachmd.com/segment/26667
- Start Date: 2024-10-30 05:00:00
- End Date: 2024-10-30 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest